Effective January 1st, Genentech will be updating the co-pay program benefit period. The program will be moving from a 12-month benefit to a calendar year benefit (January to December).
Patient benefit will automatically renew annually for all patients enrolled in the program on January 1st.
For more information, please call the Help Desk at 800-636-0316.
The information contained in this section of the site is intended for US specialty pharmacy representatives only. Click "OK" if you are a specialty pharmacy representative.
There is no physical card that you need to carry. Your specialty pharmacy just needs your Rx BIN and Member ID numbers to process your payment.
This information is shown on the screen when you enroll. It is also sent to you in a Welcome Letter.
You might want to hold on to this information, just in case. If you need to find it again, log in to your account. These numbers are shown on your Dashboard.
Give your Rx BIN and Member ID numbers to your specialty pharmacy. The specialty pharmacy will collect your out-of-pocket cost and use the program to pay the rest.
Evrysdi is a prescription medicine used to treat spinal muscular atrophy (SMA) in adults and children 2 months of age and older.
It is not known if Evrysdi is safe and effective in children under 2 months of age.
These are not all of the possible side effects of Evrysdi. For more information on the risk and benefits profile of Evrysdi, ask your healthcare provider or pharmacist.
You may report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at 1-888-835-2555.
Please see accompanying full Prescribing Information for additional Important Safety Information.